The Week in Review: BioBay Investor Forum Names Chiva Pharma and Suzhou Biologix as “Most Promising”

BioBay Investor Forum 2011 concluded a successful meeting, after selecting Chiva Pharmaceuticals and Suzhou Biologix Medical Technology as the two “Most Promising” of the presenting companies; Hua Medicine, an innovative China startup, secured $50 million to fund its drug development and commercialization efforts; Li Chen, CEO of Hua declared “Right now, the time is perfect for a China pharma startup” in an exclusive ChinaBio® Today interview; Cipla and its China partner BioMab have invested $165 million in facilities to produce biosimilars; Henan Lingrui Pharma will raise $60.5 million to expand its production capacity; China Grand Pharma will pay $17.2 million for an 81% stake in Wuhan Kernel Biotech; AstraZeneca plans to continue an emphasis on partnership in China drug development rather than M&A; Pfizer signed a China drug distribution deal with Jointown Pharmaceutical Group; and Daiichi Sankyo received SFDA approval for silodosin, a novel treatment for dysuria. More details…. Stock Symbols: (BSE: 500087) (SHA: 600285) (HK: 0512) (NYSE: AZN) (NYSE: PFE) (SHA: 600998) (TSE: 4568) Share this with colleagues:   var switchTo5x=true; stLight.options({publisher:'d7871f5b-67bc-4d30-b66f-1465d0b97213'});